CardiologyOnline.net

Cardiology Xagena

XagenaNewsletter
Xagena Mappa
Medical Meeting
Pneumobase.it

Search results for "Stent thrombosis"

The REALITY Trial is a prospective, randomized study involving 1,386 patients at 90 hospitals centers in Europe, Latin America and Asia. In the REALITY trial, patients were included if they had up ...


Patients with myocardial infarction who stopped taking antiplatelet drugs within 30 days of receiving a drug-coated stent had nine times the risk of death compared to patients who followed doctors' or ...


Stent thrombosis is a recognized complication occurring in 1-2% of patients with coronary artery disease treated by percutaneous coronary intervention ( PCI ) with stent implantation. Its occurrence i ...


Drug-eluting stents ( DES ) are extremely effective devices to prevent restenosis following angioplasty. Yet, since last year, there is some debate and persistent uncertainty regarding the long term s ...


The FDA ( Food and Drug Administration ) has approved the Endeavor Zotarolimus-eluting coronary stent for use in treating patients with narrowed coronary arteries, the blood vessels supplying the hear ...


Prasugrel ( Efient, Effient ), a new antiplatelet agent that provides higher levels of platelet inhibition than current standard therapies, could provide more consistent protection from ischemic event ...


Prasugrel ( Efient, Effient ), a new antiplatelet agent that provides higher levels of platelet inhibition than current standard therapies, could provide more consistent protection from ischemic eve ...


A randomised multicentre open-label study was evaluating the efficacy and safety of prolonged antiplatelet therapy in patients with coronary disease has found that 24 months' duration of dual therapy ...


The relation between platelet reactivity and stent thrombosis, major bleeding, and other adverse events after coronary artery implantation of drug-eluting stents has been incompletely characterised. T ...


Third-generation biodegradable polymer drug-eluting stents might reduce the risk of stent thrombosis compared with first-generation permanent polymer drug-eluting stents.The aim of a study was to inve ...


Drug-eluting stents with durable biocompatible or biodegradable polymers have been developed to address the risk of thrombosis associated with first-generation drug-eluting stents.The aim of a study w ...


Bioabsorbable vascular scaffolds were developed to overcome limitations of permanent bare-metal or drug-eluting coronary stents, ie, stent thrombosis ( despite prolonged dual antiplatelet therapy ), t ...


Safety advantages of Xience stent over Taxus stent increased between two and three years, according to long-term data.The data showed that patients treated with Xience experienced fewer myocardial inf ...


The safety and efficacy of drug-eluting stents ( DES ) in the treatment of coronary artery disease have been assessed in several randomised trials. However, none of these trials were powered to assess ...


Dual antiplatelet therapy ( DAPT ) cessation increases the risk of adverse events after percutaneous coronary intervention ( PCI ). Whether risk changes over time, depends on the underlying reason for ...